Holen Sie sich die Stockscreener-App
10.65
5.03%
0.51
Handel nachbörslich:
10.82
0.17
+1.60%
Schlusskurs vom Vortag:
$10.14
Offen:
$10.01
24-Stunden-Volumen:
776.18K
Relative Volume:
0.68
Marktkapitalisierung:
$830.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.87M
KGV:
-5.884
EPS:
-1.81
Netto-Cashflow:
$-109.90M
1W Leistung:
+4.11%
1M Leistung:
+25.74%
6M Leistung:
+28.93%
1J Leistung:
+41.62%
1-Tages-Spanne:
$9.96
$11.19
1-Wochen-Bereich:
$9.80
$11.19
52-Wochen-Spanne:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Firmenname
Oric Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 388-5600
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Vergleichen Sie ORIC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
10.65 | 830.88M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Perform |
| 2022-04-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-03-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Citigroup | Neutral |
| 2020-05-19 | Eingeleitet | Guggenheim | Buy |
| 2020-05-19 | Eingeleitet | JP Morgan | Overweight |
| 2020-05-19 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Oric Pharmaceuticals (NASDAQ:ORIC) Trading Down 3.4%Here's Why - MarketBeat
(ORIC) Trading Report - news.stocktradersdaily.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down Following Insider Selling - MarketBeat
Millennium Management LLC Has $223,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Research Analysts Issue Forecasts for ORIC FY2026 Earnings - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 2,976 Shares - MarketBeat
Oric Pharmaceuticals Elects Directors at Annual Meeting - TipRanks
What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now? - sharewise
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down After Insider Selling - Defense World
Dominic Piscitelli Sells 2,600 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock - MarketBeat
Bank of America Corp DE Acquires 28,570 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Millennium Management LLC Trims Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Brokers Issue Forecasts for ORIC FY2026 Earnings - Defense World
Insider Sell: Dominic Piscitelli Sells Shares of ORIC Pharmaceuticals Inc (ORIC) - GuruFocus
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of “Buy” from Analysts - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from Analysts - MarketBeat
Transcript : ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - MarketScreener
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpStill a Buy? - MarketBeat
Two Sigma Investments LP Decreases Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Bank of America Corp DE - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up – Here’s What Happened - Defense World
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 7.6%Still a Buy? - MarketBeat
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - mx.advfn.com
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharmaceuticals Expands Oncology Team with 45,600 Equity Grants for New Clinical Specialists - Stock Titan
ORIC Pharmaceuticals, Inc. announced that it has received $124.999983 million in funding from a group of investors - MarketScreener
Cantor Fitzgerald Estimates ORIC FY2025 Earnings - MarketBeat
Two Sigma Investments LP Decreases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 3.5%What's Next? - MarketBeat
Two Sigma Advisers LP Acquires 8,300 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Viking Invests $125 Million in ORIC Pharmaceuticals PIPE Financing - Global Legal Chronicle
Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know - MSN
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownTime to Sell? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
H.C. Wainwright maintains buy rating on ORIC Pharmaceuticals stock By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Buys New Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Wedbush Reiterates Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial - MSN
Viking in PIPE Investment in ORIC Pharmaceuticals - Cleary Gottlieb
Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oric Pharmaceuticals Inc-Aktie (ORIC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Jun 23 '25 |
Sale |
10.00 |
1,034 |
10,344 |
100,783 |
| You Angie | Director |
Jun 20 '25 |
Buy |
9.39 |
26,597 |
249,669 |
26,597 |
| You Angie | Director |
Jun 23 '25 |
Buy |
9.43 |
1,403 |
13,230 |
28,000 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 12 '25 |
Sale |
10.00 |
300 |
3,000 |
101,817 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 11 '25 |
Sale |
10.01 |
2,976 |
29,777 |
102,117 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 10 '25 |
Sale |
10.00 |
324 |
3,240 |
105,093 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 06 '25 |
Sale |
10.01 |
2,600 |
26,021 |
104,164 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 09 '25 |
Sale |
10.00 |
300 |
3,000 |
103,864 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):